Waldencast Announces Participation in the 2025 IMCAS World Congress
Waldencast (NASDAQ: WALD) announced its participation in the 2025 International Master Course on Aging Science (IMCAS) World Congress in Paris from January 30 to February 1, 2025. The event brings together industry leaders in dermatology, plastic surgery, and aging science.
CEO Michel Brousset will join a capital markets roundtable discussing medical grade skincare and the beauty industry's future. Dr. Suzan Obagi, Chief Medical Director at Obagi Medical, will deliver two presentations: one on pairing skincare with procedures and minimizing energy-based device complications, and another symposium focused on hyperpigmentation.
Waldencast (NASDAQ: WALD) ha annunciato la sua partecipazione al 2025 International Master Course on Aging Science (IMCAS) World Congress che si terrà a Parigi dal 30 gennaio al 1 febbraio 2025. L'evento riunisce leader del settore in dermatologia, chirurgia plastica e scienza dell'invecchiamento.
Il CEO Michel Brousset parteciperà a un tavolo rotondo sui mercati capitali, discutendo della skincare di grado medico e del futuro dell'industria della bellezza. La Dr.ssa Suzan Obagi, Direttore Medico di Obagi Medical, farà due presentazioni: una sull'abbinare la skincare a procedure e sulla minimizzazione delle complicazioni legate ai dispositivi basati sull'energia, e un altro simposio focalizzato sull'iperpigmentazione.
Waldencast (NASDAQ: WALD) anunció su participación en el 2025 International Master Course on Aging Science (IMCAS) World Congress en París del 30 de enero al 1 de febrero de 2025. El evento reúne a líderes de la industria en dermatología, cirugía plástica y ciencia del envejecimiento.
El CEO Michel Brousset se unirá a una mesa redonda sobre mercados de capital, discutiendo el cuidado de la piel de grado médico y el futuro de la industria de la belleza. La Dra. Suzan Obagi, Directora Médica de Obagi Medical, realizará dos presentaciones: una sobre la combinación de cuidados de la piel con procedimientos y la minimización de las complicaciones de dispositivos basados en energía, y otro simposio centrado en la hiperpigmentación.
월든캐스트 (NASDAQ: WALD)는 2025년 1월 30일부터 2월 1일까지 파리에서 열리는 2025 국제 노화 과학 석사 과정(IMCAS) 세계 총회에 참여한다고 발표했습니다. 이 행사는 피부과, 성형외과 및 노화 과학 분야의 산업 리더들을 한데 모읍니다.
CEO 미셸 브루셋은 의료 등급 스킨케어와 미용 산업의 미래에 대해 논의하는 자본 시장 원탁 회의에 참석할 예정입니다. 오바기 메디컬의 최고 의학 책임자인 수잔 오바기 박사는 두 가지 발표를 진행할 예정입니다: 하나는 스킨케어와 절차의 결합 및 에너지 기반 장치의 합병증 최소화에 관한 내용이고, 다른 하나는 과다 색소침착에 관한 심포지엄입니다.
Waldencast (NASDAQ: WALD) a annoncé sa participation au 2025 International Master Course on Aging Science (IMCAS) World Congress à Paris du 30 janvier au 1er février 2025. L'événement rassemble des leaders de l'industrie en dermatologie, chirurgie plastique et science du vieillissement.
Le PDG Michel Brousset participera à une table ronde sur les marchés des capitaux, discutant des soins de la peau de grade médical et de l'avenir de l'industrie de la beauté. Dr. Suzan Obagi, Directrice Médicale chez Obagi Medical, fera deux présentations : l'une sur l'association des soins de la peau avec des procédures et la minimisation des complications liées aux dispositifs basés sur l'énergie, et un autre symposium axé sur l'hyperpigmentation.
Waldencast (NASDAQ: WALD) gab seine Teilnahme am 2025 International Master Course on Aging Science (IMCAS) World Congress in Paris vom 30. Januar bis 1. Februar 2025 bekannt. Die Veranstaltung versammelt Branchenführer in der Dermatologie, plastischen Chirurgie und Alterswissenschaft.
CEO Michel Brousset wird an einem Runden Tisch der Kapitalmärkte teilnehmen, wo er über medizinische Hautpflege und die Zukunft der Schönheitsindustrie diskutiert. Dr. Suzan Obagi, Medizinische Direktorin von Obagi Medical, wird zwei Präsentationen halten: eine über die Kombination von Hautpflege mit Verfahren und die Minimierung von Komplikationen durch energiebasierte Geräte, und ein weiteres Symposium mit Fokus auf Hyperpigmentierung.
- None.
- None.
LONDON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform, today announced its participation in the 2025 International Master Course on Aging Science (IMCAS) World Congress, which will be held in Paris from January 30, 2025 to February 1, 2025.
The IMCAS World Congress is one of the most highly anticipated events in the dermatology, plastic surgery, and aging science community. It gathers industry leaders and executives to discuss the latest breakthroughs, innovations, and business opportunities.
Michel Brousset, Founder and Chief Executive Officer, will participate in a capital markets roundtable where he will discuss the future of medical grade skincare and the overall beauty and aesthetics industry.
Additionally, Dr. Suzan Obagi, Chief Medical Director at Obagi Medical, will participate in two sessions at the event. The first is a lecture titled “Pairing Skincare with Procedures to Enhance Results and Minimize Complications,” which will focus on the complications of energy-based devices and how to minimize the effects. The second is a scientific committee symposium focused on hyperpigmentation.
About Waldencast
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the business combination with Obagi Skincare and Milk Makeup. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com/.
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, refined with a legacy of 35 years’ experience. First known as leaders in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi products are designed to diminish the appearance of premature aging, photodamage, skin discoloration, acne, and sun damage. Backed by science and trusted by professionals, Obagi empowers individuals to achieve healthy, beautiful skin. More information about Obagi is available on the brand’s website, https://www.obagi.com.
About Suzan Obagi, MD
Suzan Obagi, MD Obagi is an Associate Professor of Dermatology and Plastic Surgery at the University of Pittsburgh Medical Center (UPMC) and serves as the director of the state-of-the-art UPMC Cosmetic Surgery and Skin Health Center. Dr. Obagi's academic commitments include clinical research, training residents in dermatologic surgery & cosmetic dermatologic surgery, and in her role as the director of the cosmetic dermatologic surgery fellowship.
Dr. Obagi has worked on various committees with the American Society for Dermatologic Surgery, has formerly served as vice president of the American Board of Cosmetic Surgery and the President of the American Academy of Cosmetic Surgery, and is a past president of the Cosmetic Surgery Foundation. In addition, Dr. Obagi trains physicians from around the world on the latest in cosmetic and laser surgery.
Contacts
Investors
ICR
Allison Malkin
investors@waldencast.com
Media
ICR
Brittany Fraser/Alecia Pulman
waldencast@icrinc.com
FAQ
When and where is Waldencast (WALD) participating in IMCAS World Congress 2025?
What topics will Waldencast's CEO discuss at IMCAS 2025?
What presentations will Dr. Suzan Obagi give at IMCAS 2025 for Waldencast?
What is the significance of IMCAS World Congress for Waldencast (WALD)?
